Cambridge Bioscience is delighted to announce a new strategic distribution partnership with EpiCypher, following our recent acquisition of Stratech Scientific, expanding access to the company’s innovative epigenetics and chromatin biology research solutions for academic, pharmaceutical and biotechnology researchers across the UK and Ireland.
The partnership will provide scientists with streamlined access to EpiCypher’s extensive portfolio of research-use-only products and services, including designer nucleosomes, chromatin mapping assays, CUT&RUN and CUT&Tag technologies, DNA methylation sequencing assays, spike-in controls, antibodies, affinity reagents, chromatin remodeling assays, and specialist assay services. These solutions are designed to support a wide range of applications in epigenetics, gene regulation, chromatin accessibility studies and drug discovery research.
EpiCypher is a US-based biotechnology company specialising in epigenetics and chromatin biology. The company is recognised for its expertise in recombinant nucleosome development and manufacturing and has built a reputation for delivering high-quality tools that help researchers investigate gene regulation, chromatin structure and function, and epigenetic mechanisms. EpiCypher’s technologies are widely used to advance scientific understanding and accelerate the development of novel therapeutics in epigenetics-focused research.
Through this partnership, Cambridge Bioscience will provide local technical support, product expertise and customer service, ensuring researchers across the UK and Ireland can fully leverage EpiCypher’s trusted portfolio of reagents, assays and services to advance their scientific discoveries.
This collaboration further strengthens Cambridge Bioscience’s commitment to supporting the UK and Ireland life science community with high-quality research tools and technologies that accelerate innovation, discovery and translational research across the fields of epigenetics and chromatin biology.
Learn more about EpiCypher’s portfolio or contact our EpiCypher specialists.